Stockreport

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update [Yahoo! Finance]

Kymera Therapeutics, Inc.  (KYMR) 
PDF FDA granted Fast Track designation to KT-621 for the treatment of moderate to severe asthma, in addition to prior Fast Track designation for moderate to severe atopic d [Read more]